Matthew Nelson
The U.S. Army has awarded AstraZeneca a $60M contract to produce an antibody drug for the prevention and treatment of SARS-CoV-2 infections.
The biopharmaceutical company will manufacture at least 100K AZD7442 treatment courses and received half of the total contract value at the time of award, the Department of Defense said Friday.
Work will take place at the drugmaker's facility in Gaithersburg, Maryland, through June 30, 2021.
AstraZeneca began testing its monoclonal antibody combination in August through a clinical trial funded by the Defense Advanced Research Projects Agency and the Biomedical Advanced Research and Development Authority.
